Texas Oncology, Dallas, TX
Ajay Dubey, Jeff Bernard, Jeffrey Limmer, Bret Heintz, Kyle Antes, Stacy Hartman, Bernard Taylor, Brennan Scott Cheek, Lalan S. Wilfong, John Russell Hoverman
Background: Metrics to assess quality are important to improve processes of care. While such capture and reporting are common in medical oncology practices, it is less common with radiation oncology. As part of a large integrated oncology practice with more than 400 physicians and 57 radiation oncologists, we explored the feasibility of capturing and reporting a bundle of metrics at each of 52 radiation oncology practice sites. Methods: At the beginning of each quarter, the first 20 charts were sampled at each rad onc site of service to capture the following metrics: performance status at the start of radiation therapy, pain level at the start of XRT for patient with bone metastasis, cancer staging documented, dose limits to normal tissue tissues established and clearly documented for IMRT cases, and adherence to the 2015 US Oncology Breast Cancer XRT Pathways. Pathways adherence was captured via physician attestation. Beginning in the second quarter, Breast Cancer Pathways concordance with the final delivered plan was reported. Beginning in the 3rdquarter, additional pathways were captured (but not reported) for NSCLC, Prostate, Rectal Cancer, and Bone Metastasis sites. Results: See table. Conclusions: Availability of metrics data and compliance was greater than 80% in all 52 radiation oncology practice sites. Documentation of dose limits was seen as an opportunity for improvement via standardization of workflows, as there were multiple workflows within the record and verify system. Concordance rate between attestation of pathways compliance and the delivered plan was high. Breast cancer pathways compliance fell in the third quarter when additional pathways were added, suggesting that increasing complexity of metrics requirements may decrease performance.
Documentation Compliance by Qtr | Performance status at the start of radiation therapy | Pain level at the start of radiation therapy for bone mets | Cancer staging | Dose limits to normal tissues | Breast pathway | Breast Pathway matches Final Delivered Plan |
---|---|---|---|---|---|---|
Qtr 1 - Jan to Mar | 89% | 94% | 95% | 81% | 91% | |
Qtr 2 - Apr to Jun | 93% | 97% | 97% | 86% | 94% | 97% |
Qtr 3 - Jul to Sep | 94% | 96% | 95% | 86% | 85% | 87% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Divya Deepak
2023 ASCO Quality Care Symposium
First Author: Tingyu WANG
2023 ASCO Annual Meeting
First Author: Arash Maghsoudi
2024 ASCO Quality Care Symposium
First Author: Olajumoke Johnson